Guanosine 5'-O-(2-thiodiphosphate) | 71376-97-1

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷酸
• 英文名称: Guanosine 5'-O-(2-thiodiphosphate)
• 英文别名: [(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydroxyphosphinothioyl hydrogen phosphate
• CAS: 71376-97-1
• 化学式: C₁₀H₁₅N₅O₁₀P₂S
• 分子量: 459.27
• InChiKey: QJXJXBXFIOTYHB-UUOKFMHZSA-N

物化性质

• 沸点：
  901.1±75.0 °C(Predicted)
• 密度：
  2.55±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -4.5
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  229
• 氢给体数：
  7
• 氢受体数：
  12

文献信息

• Methods for modulating taste receptors
  申请人：MARS, INCORPORATED

  公开号：US11185100B2

  公开（公告）日：2021-11-30

  Amino acids present in domains of an umami taste receptor are described herein, wherein the amino acids interact with at least one nucleotide derivative and/or at least one transmembrane compound that potentiates, modulates, increases, and/or enhances the activity of the umami receptor. Such compounds can be used in flavor compositions to enhance the umami taste and/or palatability of food products.

  本文描述了存在于鲜味受体结构域中的氨基酸，其中氨基酸与至少一种核苷酸衍生物和/或至少一种跨膜化合物相互作用，从而增强、调节、增加和/或提高鲜味受体的活性。此类化合物可用于调味组合物，以增强食品的鲜味和/或适口性。
• Nucleic acid ligands to integrins
  申请人：GILEAD SCIENCES, INC.

  公开号：US20020150536A1

  公开（公告）日：2002-10-17

  Methods are described for the isolation of nucleic acid ligands to integrins using the SELEX process. SELEX is an acronym for Systematic Evolution of Ligands by EXponential enrichment. The nucleic acid ligands of the present invention are useful as therapeutic and diagnostic agents.

  本文介绍了利用 SELEX 过程分离整合素的核酸配体的方法。SELEX 是英文 "Systematic Evolution of Ligands by EXponential enrichment "的缩写。本发明的核酸配体可用作治疗和诊断药物。
• Novel signaling pathway for the production of inflammatory pain and neuropathy
  申请人：The Regents of the University of California

  公开号：US20030008807A1

  公开（公告）日：2003-01-09

  This invention pertains to the discovery of a novel pathway that mediates hyperalgesia, neuropathic pain, and inflammatory pain. This pathway is a third independent pathway that involves activation of extracellular signal-regulated kinases (ERKs) 1 and 2. The pathway comprises a Ras-MEK-ERK1/2 cascade that acts independent of PKA or PKC&egr; as a novel signaling pathway for the production of inflammatory (and neuropathic) pain. This pathway presents numerous targets for a new class of analgesic agents.

  本发明涉及一种介导痛觉减退、神经性疼痛和炎症性疼痛的新型途径的发现。这条途径是第三条独立的途径，涉及细胞外信号调节激酶（ERK）1 和 2 的激活。该通路由 Ras-MEK-ERK1/2 级联组成，其作用独立于 PKA 或 PKC&egr，是产生炎性（和神经性）疼痛的新型信号通路。这一途径为新型镇痛剂提供了众多靶点。
• CNRE BINDING FACTORS AND USES THEREOF
  申请人：THE BRIGHAM AND WOMEN'S HOSPITAL, INC.

  公开号：EP1071434A1

  公开（公告）日：2001-01-31
• EP1071434A4
  申请人：——

  公开号：EP1071434A4

  公开（公告）日：2002-04-03